{
    "nctId": "NCT01803282",
    "briefTitle": "Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors",
    "officialTitle": "A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors",
    "overallStatus": "COMPLETED",
    "conditions": "Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer, Colorectal Cancer, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 236,
    "primaryOutcomeMeasure": "Percentage of Participants Experiencing Treatment-Emergent Adverse Events",
    "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Part A: histologically or cytologically confirmed advanced malignant solid tumor that is refractory to or intolerant of standard therapy or for which no standard therapy is available\n* Part B: Pancreatic Adenocarcinoma\n\n  * Presence of histologically confirmed inoperable locally advanced or metastatic pancreatic adenocarcinoma\n* Part B: NSCLC\n\n  * Stage IIIB with malignant pleural effusion/pleural seeding or stage IV histologically confirmed NSCLC\n  * Absence of known epidermal growth factor receptor (EGFR) mutation\n  * Absence of known translocation or inversion events involving the ALK gene locus (resulting in EML4-ALK fusion)\n* Part B: Esophagogastric Adenocarcinoma:\n\n  * Histologically confirmed inoperable advanced gastric adenocarcinoma (including adenocarcinoma of the gastrooesophageal junction) or relapsed gastric adenocarcinoma\n  * Human epidermal growth factor receptor 2 (HER2)-negative tumor (primary tumor or metastatic lesion)\n* Part B: First-Line Colorectal Cancer\n\n  * Histologically confirmed inoperable advanced adenocarcinoma of the colon or rectum\n  * Radiographically measureable disease\n  * No prior cytotoxic chemotherapy to treat their metastatic disease\n* Part B: Second-Line Colorectal Cancer\n\n  * Histologically confirmed inoperable advanced adenocarcinoma of the colon or rectum\n  * Radiographically measureable disease\n  * Received first-line combination therapy containing oxaliplatin and fluoropyrimidine with or without bevacizumab for metastatic disease with documented evidence of disease progression during or after treatment completion\n* Part B: Breast Cancer\n\n  * Histologically or cytologically confirmed metastatic breast cancer\n  * Radiographically measureable disease\n  * Previous hormonal therapy for metastatic breast cancer or cytotoxic adjuvant chemotherapy is allowed\n  * Treatment with weekly single-agent paclitaxel is appropriate in the opinion of the treating physician\n  * HER-2 negative tumor (primary tumor or metastatic lesion)\n* Adequate organ function\n\nKey Exclusion Criteria:\n\n* Pregnant or lactating\n* Individuals with known central nervous system (CNS) metastases, unless metastases are treated and stable and the individual does not require systemic steroids\n* Myocardial infarction, symptomatic congestive heart failure, unstable angina, or serious uncontrolled cardiac arrhythmia within the last 6 months\n* Anti-tumor therapy within 28 days of study drug dosing; concurrent use of hormone therapy for breast or prostate cancer is permitted\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}